

## Declarations of interest of experts involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

TASK FORCE MEMBER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
William Wijns	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...) - Institutional               <ul style="list-style-type: none"> <li>• Abbott Vascular</li> <li>• Biosensors</li> <li>• Biotronik</li> <li>• Boston Scientific</li> <li>• Cappella</li> <li>• Conormed</li> <li>• Cordis</li> <li>• Devax</li> <li>• Medtronic, Inc.</li> <li>• Orbus Neich</li> <li>• Prescient</li> <li>• Sorin Group</li> <li>• Terumo</li> <li>• Topspin</li> <li>• Xtent</li> <li>• Volcano</li> <li>• Glaxo SmithKline</li> <li>• Bristol Myers Squibb</li> <li>• Therabel"</li> </ul> </li> <li>⇒ All fees go to "Cardiovascular Research – Aalst (BE) (institutional research organization)</li> <li>○ Owner of a healthcare company               <ul style="list-style-type: none"> <li>• Cardio<sup>3</sup> Biosciences (cell therapy start up). Not as a personal but "Cardiovascular Research" – Aalst (BE) is a stockholder</li> </ul> </li> </ul>
Philippe Kolh	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Sanofi-Aventis</li> </ul> </li> <li>○ Others (Honoraria for lecturing)               <ul style="list-style-type: none"> <li>• Edwards Lifesciences</li> </ul> </li> </ul>
Nicolas Danchin	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Bristol Myers Squibb</li> <li>• Pfizer</li> <li>• Sanofi-Aventis</li> <li>• Servier</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Bristol Myers Squibb</li> </ul> </li> </ul>

## Declarations of interest of experts involved involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

TASK FORCE MEMBER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
		<ul style="list-style-type: none"> <li>• Pfizer</li> <li>• Sanofi-Aventis</li> <li>• Servier</li> <li>○ Others (fees for participating in symposia)               <ul style="list-style-type: none"> <li>• Boehringer Ingelheim</li> <li>• Glaxo SmithKline</li> <li>• Eli Lilly</li> <li>• Merck Sharp &amp; Dohme -Schering</li> <li>• Novartis</li> </ul> </li> </ul>
<b>Carlo Di Mario</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Eli Lilly</li> <li>• Medtronic, Inc.</li> <li>• Biosensors</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Boston Scientific</li> </ul> </li> <li>○ Others               <ul style="list-style-type: none"> <li>• Boston Scientific (Scientific Direction of the “Institute for Therapy Advancement”, Roissy, Paris, an educational center supported by BSC)</li> <li>• The Medicines (Speakers’ fees)</li> <li>• Cordis (Speakers’ fees)</li> </ul> </li> </ul>
<b>Volkmar Falk</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Mitral Solutions</li> <li>• Micardia</li> <li>• Pluromed</li> <li>• Ventor</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Mitral Solutions</li> <li>• Ventor</li> </ul> </li> </ul>
<b>Thierry A. Folliguet</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Sorin Group</li> </ul> </li> </ul>
<b>Scot Garg</b>	Yes	<ul style="list-style-type: none"> <li>○ Other (honoraria)               <ul style="list-style-type: none"> <li>• Abbott Vascular</li> </ul> </li> </ul>
<b>Kurt Huber</b>	No	

## Declarations of interest of experts involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

TASK FORCE MEMBER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
<b>Stefan James</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Astra Zeneca</li> <li>• Eli Lilly</li> </ul> </li> </ul>
<b>Juhani Knuuti</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• GE Healthcare</li> <li>• Orion Pharma</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• GE Healthcare</li> <li>• Novartis</li> </ul> </li> </ul>
<b>José Lopez Sendon</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Servier</li> <li>• Bristol Myers Squibb</li> <li>• Novartis</li> <li>• Roche</li> <li>• Eli Lilly</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Servier</li> <li>• CVT</li> <li>• Eli Lilly</li> </ul> </li> </ul>
<b>Jean Marco</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Crossroads Institute</li> <li>• Abbott Vascular</li> </ul> </li> </ul>
<b>Lorenzo Menicanti</b>	No	
<b>Miodrag Ostojic</b>	Yes	<ul style="list-style-type: none"> <li>○ Others               <ul style="list-style-type: none"> <li>• Terumo (PI of Norobi PK and Nobori Core)</li> <li>• Biosensor (PI of Stealth PK)</li> <li>• Xtent (PI of custom PK)</li> </ul> </li> </ul>
<b>Massimo Piepoli</b>	No	
<b>Charles Pirlet</b>	No	
<b>José L. Pomar</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising (teaching)               <ul style="list-style-type: none"> <li>• Edwards Lifesciences</li> <li>• Sorin Group</li> <li>• Medtronic, Inc.</li> </ul> </li> </ul>

## Declarations of interest of experts involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

TASK FORCE MEMBER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
<b>Nicolaus Reifart</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Medlogics</li> <li>• Sanofi-Aventis</li> <li>• Bridgepoint</li> </ul> </li> </ul>
<b>Flavio L. Ribichini</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Abbott Vascular (Co PI in a sponsoring study called EXECUMUE)</li> </ul> </li> </ul>
<b>Martin Jan Schalij</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Boston</li> <li>• Medtronic, Inc.</li> <li>• Biotronik</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Boston Scientific</li> </ul> </li> </ul>
<b>Paul Sergeant</b>	Yes	<ul style="list-style-type: none"> <li>○ Others               <ul style="list-style-type: none"> <li>• Medtronic, Inc. (Educational agreement between K.U. Leuven and MEDT, not with myself)</li> </ul> </li> </ul>
<b>Patrick W. Serruys</b>	No	
<b>Sigmund Silber</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Medtronic, Inc.</li> <li>• Biotronik</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Abbott Vascular</li> <li>• Boston Scientific</li> <li>• Terumo</li> <li>• Orbus-Neich</li> <li>• The Medicines Company</li> </ul> </li> </ul>
<b>Miguel Sousa Uva</b>	No	
<b>David Taggart</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Novadaq</li> </ul> </li> <li>○ Stockholder of a healthcare company               <ul style="list-style-type: none"> <li>• Novadaq</li> </ul> </li> </ul>

This table represents the relevant relationships of the above experts with industry and other entities that were reported to us at the time of publication of the guidelines

## Declarations of interest of experts involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

TASK FORCE REVIEWER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
Peter Kearney	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Astra Zeneca</li> <li>• Sanofi-Aventis</li> <li>• Menarini</li> <li>• Merck Sharp &amp; Dohme</li> <li>• Philips</li> <li>• Medtronic</li> </ul> </li> </ul>
Ludwig von Segesser	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Symetis SA, Lausanne</li> </ul> </li> <li>○ Owner of a healthcare company (or partnership)               <ul style="list-style-type: none"> <li>• Smartcanula LLC, Lausanne</li> </ul> </li> </ul>
Stefan Agewall	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Astra Zeneca</li> </ul> </li> </ul>
Alexander Aladashvili	No	
Dimitrios Alexopoulos	No	
Manuel J. Antunes	No	
Enver Atalar	No	
Aart Brutel de la Riviere	No	
Alexander Doganov	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Medtronic, Inc.</li> <li>• Terumo</li> </ul> </li> </ul>
Jaan Eha	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Servier</li> <li>• Novartis Pharma</li> <li>• Amgen</li> <li>• Sanofi-Aventis</li> </ul> </li> </ul>
Jean Fajadet		<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Cordis</li> </ul> </li> </ul>
Rafael Ferreira	No	
Jerome Garot	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Servier</li> </ul> </li> </ul>

## Declarations of interest of experts involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

TASK FORCE REVIEWER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
<b>Julian Halcox</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Astra Zeneca</li> <li>• Solvay</li> <li>• Servier</li> <li>• Pfizer</li> <li>• Sanofi-Aventis</li> <li>• Merck Sharp &amp; Dohme</li> </ul> </li> </ul>
<b>Yonathan Hasin</b>	No	
<b>Stefan Janssens</b>	No	
<b>Kari Kervinen</b>	No	
<b>Gunther Laufer</b>	No	
<b>Victor Legrand</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Cordis, Johnson and Johnson</li> </ul> </li> </ul>
<b>Samer Nashef</b>	No	
<b>Franz-Josef Neumann</b>	No	
<b>Kari Niemela</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Boston Scientific</li> <li>• Medtronic, inc.</li> </ul> </li> </ul>
<b>Petros Nihoyannopoulos</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts (such as grants, etc...)               <ul style="list-style-type: none"> <li>• Bracco Pharmaceuticals</li> </ul> </li> </ul>
<b>Marko Noc</b>	No	
<b>Jan Jacob Piek</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Abbott Vascular</li> </ul> </li> </ul>
<b>Jan Pirk</b>	No	
<b>Joseph Rozenman</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Boston Scientific</li> <li>• Medtronic, Inc.</li> <li>• Abbott Vascular</li> <li>• Pfizer</li> </ul> </li> </ul>

## Declarations of interest of experts involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

TASK FORCE REVIEWER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
		<ul style="list-style-type: none"> <li>• Sanofi-Aventis</li> <li>• Merck Sharp &amp; Dohme</li> <li>• Eli Lilly</li> </ul>
<b>Manel Sabate</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Cordis, Johnson and Johnson</li> <li>• Abbott Vascular</li> <li>• Medtronic, Inc.</li> </ul> </li> </ul>
<b>Radovan Starc</b>	No	
<b>Matthias Thielmann</b>	No	
<b>David Wheatley</b>	No	
<b>Stephan Windecker</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Abbott Vascular</li> <li>• Biosensors</li> <li>• Boston Scientific</li> <li>• Cordis and Medtronic</li> </ul> </li> <li>○ Others (Lectures fees)               <ul style="list-style-type: none"> <li>• Johnson and Johnson</li> <li>• Edwards Lifesciences</li> <li>• Eli Lilly</li> <li>• Astra Zeneca</li> <li>• Abbott Vascular</li> <li>• Biosensors</li> <li>• Boston Scientific</li> <li>• Medtronic, Inc.</li> </ul> </li> </ul>
<b>Marian Zembala</b>	No	

This table represents the relevant relationships of the above experts with industry and other entities that were reported to us at the time of publication of the guidelines

## Declarations of interest of experts involved involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

CPG MEMBER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
<b>Alec Vahanian</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Edwards Lifesciences</li> </ul> </li> </ul>
<b>Angelo Auricchio</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Medtronic, Inc.</li> <li>• Boston Scientific</li> <li>• Sorin Group</li> <li>• Biotronik</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Medtronic, Inc.</li> <li>• EBR System</li> <li>• Sorin Group</li> <li>• Biotronik</li> <li>• Merck Sharp &amp; Dohme</li> <li>• Biosense Webster</li> <li>• Philips</li> </ul> </li> <li>○ Speaker fee               <ul style="list-style-type: none"> <li>• Sorin Group</li> <li>• Medtronic, Inc.</li> <li>• Biotronik</li> <li>• St Jude Medical</li> <li>• Abbott Vascular</li> <li>• Boston Scientific</li> </ul> </li> </ul>
<b>Jeroen Bax</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Edwards Lifesciences</li> <li>• Biotronik</li> <li>• GE Healthcare</li> <li>• Bristol Myers Squibb Medical Imaging/Lantheus</li> <li>• St Jude Medical</li> <li>• Medtronic, Inc.</li> </ul> </li> </ul>
<b>Claudio Ceconi</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Servier Laboratories</li> </ul> </li> </ul>

## Declarations of interest of experts involved involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

CPG MEMBER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
<b>Gerasimos Filippatos</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Brahms</li> <li>• Vifor</li> <li>• Nanosphere</li> <li>• Roche Diagnostics</li> </ul> </li> </ul>
<b>Christian Funck-Brentano</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Pierre-Fabre Laboratories</li> <li>• Servier Laboratories</li> <li>• Johnson &amp; Johnson</li> <li>• Janssen-Cilag</li> <li>• Trophos</li> <li>• Cephalon</li> <li>• Sigma-Tau</li> <li>• MMV</li> </ul> </li> </ul>
<b>Richard Hobbs</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Pfizer</li> <li>• Roche</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• A2</li> <li>• Pfizer</li> <li>• Takeda</li> </ul> </li> </ul>
<b>Peter Kearney</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Astra Zeneca</li> <li>• Sanofi-Aventis</li> <li>• Menarini</li> <li>• Merck Sharp &amp; Dohme</li> <li>• Philips</li> <li>• Medtronic</li> </ul> </li> </ul>
<b>Theresa McDonagh</b>	No	
<b>Bogdan Popescu</b>	No	
<b>Zeljko Reiner</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Pfizer</li> <li>• Sanofi-Aventis</li> <li>• Solvay</li> <li>• Glaxo SmithKline</li> </ul> </li> </ul>

## Declarations of interest of experts involved in the ESC/EACTS Guidelines on Myocardial Revascularisation

CPG MEMBER NAME	RELATIONSHIP WITH INDUSTRY	TYPE OF RELATIONSHIP
<b>Udo Sechtem</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Boehringer Ingelheim</li> <li>• Merck Sharp &amp; Dohme</li> <li>• Sanofi-Aventis</li> <li>• Bayer AB</li> </ul> </li> </ul>
<b>Per Anton Sirnes</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Boehringer Ingelheim</li> <li>• Sanofi-Aventis</li> </ul> </li> </ul>
<b>Michal Tendera</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• Servier</li> <li>• Bayer Healthcare</li> <li>• Amgen</li> <li>• C-Cure</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Servier</li> <li>• Bayer Healthcare</li> </ul> </li> </ul>
<b>Panos Vardas</b>	Yes	<ul style="list-style-type: none"> <li>○ Research contacts               <ul style="list-style-type: none"> <li>• St Jude Medical</li> <li>• Medtronic, Inc.</li> </ul> </li> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• St Jude Medical</li> <li>• General Electric</li> <li>• Medtronic, Inc.</li> <li>• Sanofi-Aventis</li> </ul> </li> </ul>
<b>Petr Widimsky</b>	Yes	<ul style="list-style-type: none"> <li>○ Consulting/Advising               <ul style="list-style-type: none"> <li>• Eli Lilly</li> <li>• Boston Scientific</li> <li>• CL Biopharma</li> <li>• Sanofi-Aventis</li> <li>• Medtronic, Inc.</li> <li>• Servier</li> </ul> </li> </ul>

This table represents the relevant relationships of the above experts with industry and other entities that were reported to us at the time of publication of the guidelines